GlassScriptPhysician profile
Mohammad Shakir
NPI 1578515862
$6,058.92
in general payments reported to CMS, 2019-2025
32 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $435 · 2021: $626 · 2022: $660 · 2023: $1,170 · 2024: $1,526 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,795 · Education: $66.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,794.64 |
| Education | $66.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,198.90 | 2019-2025 | Tavneos, Enbrel, Evenity |
| Pfizer INC. | $1,045.14 | 2019-2025 | |
| Abbvie INC. | $807.61 | 2019-2025 | Rinvoq, Skyrizi |
| Glaxosmithkline, LLC. | $436.87 | 2020-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $342.09 | 2022-2025 | Acthar |
| Horizon Therapeutics Plc | $219.01 | 2020-2023 | Krystexxa |
| Janssen Biotech, INC. | $216.25 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $203.00 | 2019-2025 | Orencia |
| Lilly USA, LLC | $196.60 | 2019-2024 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.92 | 2020-2025 | Cyltezo, Jascayd |
| Novartis Pharmaceuticals Corporation | $146.60 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $145.62 | 2019-2021 | |
| Ucb, INC. | $126.09 | 2022-2025 | Bimzelx, Cimzia |
| Organon LLC | $115.75 | 2023-2025 | Hadlima, Renflexis |
| Genentech USA, INC. | $82.34 | 2023-2025 | Actemra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $80.13 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $80.09 | 2022-2025 | Opsumit |
| Astrazeneca Pharmaceuticals LP | $74.14 | 2022-2023 | Saphnelo, Evusheld |
| Sandoz INC. | $70.10 | 2023-2025 | Hyrimoz, Jubbonti |
| Mylan Institutional INC. | $43.88 | 2023 | Hulio |
| Celltrion USA INC. | $43.61 | 2023-2025 | Yuflyma, Vegzelma |
| Kiniksa Pharmaceuticals, LTD. | $29.02 | 2023 | Arcalyst |
| Teva Pharmaceuticals USA, INC. | $27.48 | 2023 | Truxima |
| Qiagen, LLC | $24.78 | 2022 | |
| Fresenius Kabi USA, LLC | $23.15 | 2023 | |
| Abbott Laboratories | $20.35 | 2023 | Cardiomems |
| Kedrion Biopharma, INC. | $19.06 | 2024 | Kedrab, Koate, Gammaked |
| Ultragenyx Pharmaceutical INC. | $18.97 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $18.90 | 2024 | Zilretta |
| Shorla Oncology INC. | $17.45 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $14.55 | 2025 | |
| Edwards Lifesciences Corporation | $13.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Shakir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.